# Epitalon: full monograph (Epitalon Rx)
> Source page: https://epithalonrx.com/monograph

Status: Compounded, not FDA-approved
Disclosure: Epitalon is not FDA approved. It is sold for research use; no human efficacy has been established, and FDA has proposed not to permit it in compounded drugs.
Not the same substance as: Epithalamin; Epithalamine; Pineamin
Updated: 2026-08-14

## Key facts
- Status: Compounded, not FDA-approved
- Human half-life: Not established (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Human subcutaneous bioavailability: Not established (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Human Cmax or AUC: Not established (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Published human PK studies: 0 (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Registered clinical trials: 0 (source: https://clinicaltrials.gov/search?term=epitalon)
- Class: Synthetic pineal tetrapeptide, derived from the pineal peptide extract Epithalamin (source: https://pubchem.ncbi.nlm.nih.gov/compound/219042)
- Sequence: Ala-Glu-Asp-Gly (AEDG) (source: https://pubchem.ncbi.nlm.nih.gov/compound/219042)
- Molecular weight: 390.35 Da (C14H22N4O9) (source: https://pubchem.ncbi.nlm.nih.gov/compound/219042)
- CAS: 307297-39-8 (source: https://pubchem.ncbi.nlm.nih.gov/compound/219042)
- US FDA status: Not approved for any use; listed on FDA's compounding safety-risks page under substances nominated but withdrawn (source: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm)
- July 2026 PCAC: FDA proposed Epitalon (free base) and Epitalon acetate NOT be added to the 503A Bulks List (source: https://www.fda.gov/media/193342/download)
- Provenance concentration: 111 of 167 indexed records (66.5 percent) come from the originating research network (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Khavinson as author: 100 of 167 records (59.9 percent) (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Independent human studies: 0 (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Randomized trials of epitalon: 0 (the epithalamin extract literature has 5) (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Meta-analyses and systematic reviews: 0 (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Registered trials (ClinicalTrials.gov): 0 (source: https://clinicaltrials.gov/search?term=epitalon)
- Human pharmacokinetics: None published (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Established human dose: None; published regimens disagree by up to four orders of magnitude (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Indexed literature: 167 Europe PMC records; 52 Russian-language (source: https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22)
- Independent in vitro replication: Yes, Brunel University London, 2025, 22 years after the original claim (source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/)
- Best rodent lifespan result: No change in mean lifespan; maximum lifespan plus 12.3 percent (source: https://europepmc.org/article/MED/14501183)
- Route as sold: Subcutaneous injection after reconstitution of a lyophilized vial (source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/)

## What is epitalon?
Epitalon is a synthetic chain of four amino acids, Ala-Glu-Asp-Gly, with the molecular formula C14H22N4O9 and a molecular weight of 390.35  [7]. It is also written epithalon, and in the more recent literature it is usually called the AEDG peptide. All three names describe the same molecule.
It was not discovered as a drug candidate and then tested. It was carved out of something older. In the 1970s a Soviet research group began studying Epithalamin, a peptide preparation extracted from the pineal gland of cattle, as a geroprotector. Epitalon is the short synthetic sequence identified from that work  [38,35,17]. That lineage explains almost everything unusual about the evidence, including the fact that the famous longevity numbers were produced by the extract rather than by the peptide.
In the United States epitalon is not a medicine. No FDA-approved product contains it, FDA lists it among bulk substances that may present significant safety risks in compounding, and in July 2026 FDA proposed that it not be added to the list of substances pharmacists may compound with  [5,1,2]. It reaches American buyers as a research chemical in a vial.
This monograph grades every claim by the species it was measured in and by who measured it. That second column matters more here than for any other compound in this fleet, and the section below explains why.

## Key facts at a glance
The fact chips on this page are sourced individually. The short version: a four-amino-acid peptide, no approved product anywhere in the United States, no established human dose, no published human pharmacokinetics, no registered trial, no randomized trial of the peptide itself, and a literature two thirds of which comes from the laboratory that created it.

## Regulatory status in the United States
Epitalon is not FDA approved. It is sold for research use; no human efficacy has been established, and FDA has proposed not to permit it in compounded drugs.
Each part of that is separately checkable. A Drugs@FDA query for epitalon as an active ingredient returns no matches, and the same query for the spelling epithalon also returns no matches  [5]. There is no approved product, no approved indication and no approved strength.
FDA lists Epitalon on its page of bulk drug substances that may present significant safety risks in compounding, in the table of substances nominated but withdrawn  [1]. The agency's stated concern is specific and worth quoting rather than paraphrasing: compounded drugs containing epitalon "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities", FDA "has not identified safety-related information regarding epitalon for the proposed route of administration", and therefore "the agency lacks sufficient information to know whether the drug would cause harm if administered to humans"  [1].
Epitalon appears in no category of FDA's interim 503A bulk-substance category list dated May 14, 2026  [4]. It is not in the group of substances that may be compounded under an interim policy while FDA evaluates them. It is outside that framework entirely.

## What happened at the July 2026 advisory committee meeting
On July 23 and 24, 2026, FDA brought seven peptide substances to the Pharmacy Compounding Advisory Committee. Epitalon was on the July 24 morning agenda. FDA's Points to Consider, items 11 and 12, read: "FDA is proposing that Epitalon (free base) NOT be included on the 503A Bulks List" and "FDA is proposing that Epitalon acetate NOT be included on the 503A Bulks List"  [2].
Two things about that proposal are commonly misread. The first is what inclusion would have meant. The 503A Bulks List does not confer approval. It governs what a licensed pharmacist may compound with, inside the statutory exemptions from new drug approval, from labeling with adequate directions for use, and from current good manufacturing practice requirements  [2]. Epitalon would not have become an approved medicine if the answer had gone the other way.
The second is what the briefing document actually contains. It is eight pages: an agenda, the four evaluation criteria from the 2019 final rule, the nominations, and the points to consider  [2]. Under the epitalon section, the sub-heading "FDA Evaluation" has no text beneath it. The substantive review is referred to as linked background material and is not resolvable from the document itself. So this site quotes the proposal, which is written down, and does not attribute reasons to FDA that the document does not state  [2].
Both nominations to add epitalon had already been withdrawn by the nominators, LDT Health Solutions on behalf of the International Peptide Society, and Wells Pharmacy Network. FDA elected to present the substance to the committee anyway  [2]. That is an unusual thing for an agency to do and it says something about how the agency views the substance.
FDA's own caveat is on page one: the agency "does not intend to issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized", and the final determination "may be affected by issues not discussed at the advisory committee meeting"  [2]. The rulemaking is pending. No vote tally for epitalon was posted on FDA's meeting page when this page was built, so this site states the proposal and makes no claim about how the committee voted  [3].

## Who actually studied epitalon
Here is the fact that reorganizes everything else on this page. Of the 167 records a four-term Europe PMC query returns for this peptide, 111 carry Vladimir Khavinson or Vladimir Anisimov as an author, or name the St. Petersburg Institute of Bioregulation and Gerontology in the affiliation. That is 66.5 percent. Khavinson alone is a named author on 100 of the 167, which is 59.9 percent of everything written about the compound  [44,41].
This is stated as provenance, not as an accusation. Khavinson's institute did the original work, published it, and has kept publishing it for four decades. That is what a research program looks like. The problem is not that the group exists; it is that when a reader is told epitalon is backed by decades of research, the decades and the research are very largely one group's.
The definition used here is deliberately generous to the network and strict about independence. A paper counts as independent only if no author from that network appears on it at all. By that rule the independent literature is real but small, and it is entirely in cells and animals: a Tbilisi State University group working on chromatin in lymphocyte cultures, a Shanxi Medical University group on mouse oocytes, a Gyeongsang National University group on bovine oocytes, and, most substantially, Brunel University London on telomere length in human cell lines in 2025  [32,35,36,10].
No laboratory outside that network has published a study in which epitalon was given to a human being  [44]. Every human record, including the mortality-reduction work that sells the compound, carries an author from the group that created it  [13,14,18].
The honest way to hold this is not suspicion. It is that a single-source literature has not yet been tested the way medicine tests things: by someone with no stake in the answer trying to get the same result and reporting it either way.

## Epitalon and Epithalamin are not the same substance
Epithalamin is a peptide complex extracted from the pineal gland. Epitalon is a synthetic tetrapeptide. The literature says so plainly: one 2007 abstract distinguishes "Epithalamin, a complex of peptides isolated from the pineal gland" from "Epitalon, synthetic tetrapeptide" in a single sentence  [17].
This matters because the human evidence splits cleanly along that line, and it splits the wrong way for the marketing. The 266-person study titled "Peptides of pineal gland and thymus prolong human life" tested Thymalin and Epithalamin. It does not mention epitalon  [13]. The 15-year follow-up in elderly coronary patients tested epithalamin courses  [14]. The circadian melatonin work in elderly subjects tested epithalamin  [15].
Run the same publication-type query over both literatures and the split becomes a number. Five records in the epithalamin corpus carry a Randomized Controlled Trial tag. Zero records in the epitalon corpus do  [43,42].
The conflation is not only a marketing habit; it is baked into reference data. PubChem's synonym list for the tetrapeptide CID 219042 includes both Epithalamin and Epithalamine  [7]. If the chemical databases blur it, a vendor page will certainly blur it, usually in the direction of borrowing the extract's mortality figures for the peptide in the vial.
One more source-level oddity belongs here rather than in a footnote: the 15-year follow-up paper's title says the geroprotector is from the pituitary gland while its own abstract says pineal gland  [14]. Both strings are in the same indexed record. It is quoted here as published.

## What the research shows, by species and by who ran it
The evidence table below has 32 rows. Each carries the species it was measured in, the grade of the design, and a provenance value: originating group, collaboration, or independent. Five rows record things that do not exist and are printed at the same weight as the findings.
Read at a glance, the file looks like this. The mechanism work is in cells and it is genuinely interesting. The lifespan and tumor work is in mice, rats and flies and is mixed, including outright null results on mean lifespan. The human work is thin, uncontrolled and almost entirely about a different substance. And 21 of the 27 non-absence rows come from the originating network or a collaboration with it.
That is not a dismissal. It is a map. A compound can be worth studying and still have no evidence that supports what is written on the label of the vial someone is about to inject.

## Does epitalon lengthen telomeres? The evidence at its true grade
This is the claim epitalon is sold on, and it is the claim that most rewards being split into grades.
In vitro, in human cells, the answer is yes, and it now has independent support. The original 2003 experiment added epithalon to telomerase-negative human fetal fibroblast culture and reported induction of the telomerase catalytic subunit, telomerase enzyme activity and telomere elongation  [8]. A 2004 follow-up in fibroblasts from a 24-week fetus reported telomeres relengthening in senescent cells and 10 extra divisions past the control's limit of 34 passages, which is where the phrase overcoming the Hayflick limit comes from  [9]. Both were done by the originating group.
Twenty-two years later, an independent laboratory at Brunel University London reproduced dose-dependent telomere lengthening in human cell lines, quantitatively, with hTERT expression and telomerase activity in normal cells and alternative lengthening of telomeres in cancer cells  [10]. This is the most important recent development in the file and it is worth saying without hedging: the in vitro telomerase claim has now been replicated by people with no stake in it.
Three details from that same paper belong next to it, because they are in the paper and not on any vendor page. At its lowest concentration the peptide SHORTENED telomeres in one cancer line. The authors name their main limitation as being a two-dimensional in vitro study and call for in vivo animal work. And the article carries a published correction replacing three figures, issued about two months after publication; it is a correction, not a retraction  [10,11].
The lengthening seen in the cancer lines ran through alternative lengthening of telomeres, a mechanism cancer cells use to keep dividing  [10]. The authors read the normal-cell result as reassuring. A reader deciding whether to inject a telomerase activator should see the cancer-cell result too, stated neutrally: it happened, in a dish, in two breast cancer lines.
In people, the answer is that nobody has measured it. There is no study in which epitalon was given to a person and their telomeres were then measured  [41]. The study usually cited for the human claim treated blood lymphocytes from 11 men in a dish. Telomere length changed significantly in 7 of them: it increased in 5, by 41, 55, 156, 18 and 76 percent, and DECREASED in 2, by 37 and 15 percent  [12]. The authors describe the pattern as a tendency toward normalization, rising in donors below the group mean and falling in donors above it  [12]. That is a different claim from lengthening, and it is the claim the source actually makes.

## The longevity cohort studies: what they can and cannot show
The mortality numbers are real publications. They are also, all of them, about Epithalamin.
The largest is a clinical assessment of 266 elderly people over 6 to 8 years, with the bioregulators given in the first 2 to 3 years. It reports mortality reductions of 1.6 to 1.8 fold in the Epithalamin group, 2.0 to 2.1 fold with Thymalin, 2.5 fold with both, and 4.1 fold in a subgroup given both annually for six years  [13]. The abstract states no allocation method, no confidence intervals and no p values, and the paper is authored by the developers of both preparations at the institute that created them  [13,44].
The strongest single study is the 15-year follow-up: 39 elderly coronary patients given six courses of epithalamin over three years alongside basic therapy, against 40 patients on basic therapy alone, with significantly lower mortality reported in the treated group  [14]. It describes itself as a randomized comparative study. That is a genuine randomized signal and it deserves to be called one. It is also 79 people, in one center, from the same research network, about the extract rather than the peptide.
What these studies can show: that a research group treating elderly patients with pineal peptide preparations over years reported better survival and better cardiovascular indices than their comparison groups. That is a real observation and it is why the compound is interesting at all.
What they cannot show: that epitalon does this. None of them tested it. They cannot show a dose, because the abstracts do not state one. They cannot separate the peptide effect from the effect of being in a long-running clinical program with regular follow-up. And they have not been replicated by anyone outside the network that ran them  [44].
One finding inside this group is worth carrying forward because it undercuts a marketing line rather than supporting it. In healthy elderly subjects, epithalamin raised night-time melatonin only in people whose pineal function was already low, and melatonin TENDED TO FALL in people whose pineal function was normal  [15]. The reported effect is a normalization, not an increase.

## The animal record, including the results that did not work
The rodent literature is the largest positive body of evidence for this compound, and it is more interesting when the nulls are left in.
In female SHR mice treated monthly from 3 months of age until natural death, epitalon did not change mean lifespan at all  [21]. What it did change was narrower: the lifespan of the last 10 percent of survivors rose 13.3 percent, maximum lifespan rose 12.3 percent, chromosome aberrations fell 17.1 percent, and leukemia incidence fell 6-fold with no change in total tumor incidence  [21]. That is a real result. It is not life extension.
Two rat studies point the same way with a twist. Under a standard day and night cycle the peptide did not change lifespan. Effects appeared only in rats whose lives had already been shortened by constant or northern natural illumination  [25,26]. Read plainly, the geroprotector rescued a stressor rather than extending a normal life.
The strongest positive lifespan result, 13.5 percent longer mean lifetime in HER-2/neu transgenic mice, sits on a published dose of 1 mg subcutaneously  [22]. Every neighbouring study in the same literature uses 0.1 to 1.0 micrograms. That is roughly a thousandfold gap, and it most likely reflects a units error in the source. It is reproduced here as published rather than quietly corrected, and it is flagged wherever the number appears.
The tumor work is more consistent than the lifespan work. Fewer and smaller mammary tumors in transgenic mice with a 3.7-fold fall in HER-2/neu mRNA  [23]; colon tumors per rat down from 4.1 to 2.7, though carcinomas still developed in 90 to 100 percent of animals  [24]; no metastases in treated C3H/He mice against 3 of 9 tumor-bearing controls  [29]; 17.9 to 30.1 percent fewer chromosome aberrations across three mouse strains where melatonin did nothing  [30].
One control result from the same experiments deserves its own line. The comparison peptide Vilon significantly INCREASED mammary cancer incidence in the mice that received it  [23]. Short peptides are not benign as a class, and the same laboratory that reported the good result reported that one.
The nearest thing to human-relevant physiology is a primate study: evening melatonin synthesis stimulated and the cortisol rhythm normalized in senescent rhesus monkeys, with no animal count in the abstract  [28]. And the oldest positive result is in fruit flies, where lifespan rose 11 to 16 percent with no dose-response across five orders of magnitude, which the authors themselves remark on  [27].

## Human evidence: what exists and what does not
Strip out the extract studies and the cell-culture studies, and the list of research in which epitalon itself entered a human body is one paper long.
It is a 2002 report on retinitis pigmentosa, and it is the only record in the whole epitalon corpus carrying a Clinical Trial publication tag  [18,43]. Its abstract reports "a positive clinical effect in 90% of the cases" and does not state how many patients there were, what the control was, how they were allocated, or what was measured. It reports a Campbell rat experiment and the patient result in the same four sentences.
Everything else described as human is cells from humans, treated in a dish. Lymphocytes from people aged 76 to 80 showing chromatin decondensation  [31]. Lymphocytes from 11 men showing bidirectional telomere changes  [12]. Cultures from tuberculosis and breast cancer patients showing partial protection against genome instability  [34,33]. Lymphocytes from people aged 75 to 88, in the Tbilisi work, showing the same chromatin effect the originating group reports  [32]. These are legitimate experiments. They are not evidence about what happens to a person.
And the absences are as informative as the presences. Zero randomized trials of epitalon. Zero meta-analyses. Zero systematic reviews  [43]. Zero registered studies on ClinicalTrials.gov  [6]. Zero studies from any laboratory outside the originating network in which epitalon was given to a person  [44].

## Where the popular claims come from
Five claims carry most of the marketing for this compound. Each traces to a real source, and each source says something narrower than the claim.
"Activates telomerase" traces to a 2003 experiment in telomerase-negative human fetal fibroblast culture, since independently reproduced in human cell lines  [8,10]. True, in a dish.
"Lengthens telomeres in humans" traces to blood lymphocytes from 11 men treated in a dish, where telomere length rose in 5 donors and fell in 2  [12]. The source calls it a tendency toward normalization.
"Reduces mortality" and "proven to extend human lifespan" trace to cohort studies of Epithalamin, the pineal extract, run and reported by the developers of both preparations  [13,14]. Those studies did not test epitalon.
"Restores melatonin" traces to work in which the extract raised melatonin only in people whose pineal function was already low, and lowered it in people whose function was normal  [15], plus a primate study with no stated animal count  [28].
"No side effects" traces to sentences inside efficacy papers written by the originating group, not to any safety study  [17,29].
"Extends lifespan in animals" traces to a literature whose best-designed mouse study found no change in mean lifespan  [21].

## Pharmacokinetics
There is no human pharmacokinetic profile of epitalon to summarize. Across 167 archived records, not one reports a human half-life, bioavailability figure, Cmax or AUC for any route  [41]. A 2026 review preprint states the same absence independently, and is cited here as corroboration of a gap rather than as evidence of an effect  [40].
This is not a small gap. Without a pharmacokinetic study nobody can say what fraction of an injected dose survives, how long it persists, or whether two people using the same stated dose reach remotely similar exposure. Every one of the chips below is an honest blank.

## Forms and routes
Epitalon reaches American buyers as a lyophilized powder in a sealed vial, reconstituted with bacteriostatic water and injected subcutaneously. There is no oral form with any evidence behind it, no nasal form in the literature, and no approved form of any kind.
The vial has no product label in the regulatory sense: no assigned strength, no expiry set by any authority, no directions for use, and no manufacturing standard behind the number printed on it  [5,1]. When a reconstitution calculator on any site tells a buyer their vial contains a given number of milligrams, that figure came from the seller and from nowhere else.
It is worth noting how ordinary this is even in research. The independent 2025 laboratory bought its epitalon from a research-chemical vendor and recorded dissolving 10 mg in 4 mL of bacteriostatic water to reach 2.5 mg/mL  [10]. That is the same arithmetic, on the same kind of material, in a university laboratory.

## Doses used in research, and why none of them is a dose for you
There is no established human dose of epitalon. No dose-finding study has ever been published, no approved product exists from which a strength could be taken, and the doses that appear in the literature disagree by up to four orders of magnitude  [41].
The rodent studies cluster at 0.1 to 1.0 micrograms per animal, given on five consecutive days each month or five days a week  [21,24,29]. One outlier states 1 mg per mouse  [22]. The cell-culture work runs 0.1 to 1.0 micrograms per mL, or 0.1 mM  [10,35]. The human reports state no dose at all: the retinitis pigmentosa paper gives none, and the epithalamin cohort studies describe courses without stating milligrams  [18,13,14].
The study-dose explorer on this site shows every regimen with the study that used it, its species, its design and its provenance. It computes nothing that looks like a recommendation, because there is nothing to recommend from.

## Is epitalon safe?
Nobody knows, and that is the accurate answer rather than a cautious one.
No dedicated human safety study of epitalon exists. No toxicology study exists. No adverse-event surveillance exists. No long-term human data at any dose exists  [41].
The reassuring statements that circulate are real sentences from real papers, and they are not safety findings. "Having no side effects" appears inside a 2007 efficacy abstract from the originating group  [17]. "Long-term exposure to Epitalon in small doses did not show any toxic effect" appears inside a 6.5-month mouse carcinogenesis study whose design measured tumors, not toxicity  [29].
Against them sit three things. FDA states it "lacks sufficient information to know whether the drug would cause harm if administered to humans" and flags immunogenicity risk from aggregation and peptide-related impurities in compounded preparations  [1]. The independent 2025 work found telomere lengthening in breast cancer cell lines through alternative lengthening of telomeres, the mechanism cancer cells use to keep dividing  [10]. And in the originating group's own mouse experiments, the comparison peptide Vilon significantly increased cancer incidence, which is a direct demonstration that short peptides are not safe as a class  [23].
Add the absence of any pharmacokinetic study  [41] and the position is simple: the exposure is unmeasured, the safety is unstudied, and the product has no quality standard.

## What side effects have been reported?
There is no systematic adverse-event record for epitalon, because no study was designed to collect one and no surveillance system covers a research chemical.
The literature contains assertions of absence rather than counts of events: no side effects in one abstract, no toxic effect in another, both from within efficacy papers by the originating network  [17,29].
An absence of reported side effects in a literature that never looked for them is not a safety profile. It is a blank page. FDA describes the same blank page in its own words when it says it lacks sufficient information to know whether the drug would cause harm in humans  [1].

## What interacts with epitalon, and who has not been studied?
No interaction study of epitalon with any drug has been published. With no pharmacokinetic data at all, there is not even a mechanism-level basis for predicting one  [41].
The populations never studied are almost everyone: no data in pregnancy or breastfeeding, none in children or adolescents, none in kidney or liver impairment, none in people taking any specific medication, and none in anyone with a current or past cancer diagnosis, which the alternative-lengthening finding in cancer cell lines makes a live question rather than a formality  [10].
The one signal the literature does offer about combinations is indirect and cautionary: in the same mouse experiments, the related short peptide Vilon made cancer outcomes significantly worse  [23]. Peptide effects in this family are not interchangeable and not uniformly benign.
The melatonin work adds a second reason for caution about stacking. In elderly people the extract raised night melatonin in those with low pineal function and lowered it in those with normal function  [15]. A compound whose direction of effect depends on baseline is a poor candidate for casual combination with sleep or hormone products.

## Where does the epitalon sold in the United States come from?
It comes from research-chemical suppliers. There is no approved manufacturer, no compounding pathway currently open to it, and no product-level quality standard anywhere in the chain.
The compounding route is the part most often misunderstood. Epitalon sits on FDA's safety-risks page under substances nominated but withdrawn  [1]. Both nominations to allow it in 503A compounding were withdrawn by the nominators, and FDA presented it to the advisory committee anyway with a proposal not to include it  [2]. It appears in no category of the interim list  [4].
What a buyer therefore receives is a sealed vial of powder whose mass, purity and identity rest entirely on the seller's word. FDA's specific technical concern about this class of preparation is aggregation and peptide-related impurities, which are exactly the failure modes a certificate of analysis from the seller is least able to rule out  [1].
For calibration, note what a university laboratory does: the independent 2025 replication also bought from a research-chemical vendor, and its methods section reports no certificate of analysis, purity figure or independent identity confirmation  [10].

## Storage and stability
No stability data for epitalon has been published: no shelf life for the lyophilized powder, no in-use stability for a reconstituted vial, and no compatibility data for any diluent  [41].
The general handling described in the research literature is the ordinary handling of a lyophilized peptide: powder kept cold and dry, reconstituted with bacteriostatic water immediately before use, and refrigerated after reconstitution  [10]. That is laboratory practice, not a storage instruction from any authority, and no expiry attaches to it.
Because FDA's stated concern for this class is aggregation and peptide-related impurities  [1], storage matters more here than for a compound with a real label, and there is less to go on.

## What we do not know
What is unresolved about epitalon is structural rather than incidental, and the full evidence-limits block follows below. In short: 66.5 percent of the literature comes from the network that created the compound  [44]; no laboratory outside it has ever given epitalon to a person  [44]; the mortality evidence belongs to a different substance  [13]; and there is no human pharmacokinetic study  [41], no registered trial  [6], no randomized trial of the peptide  [43], no dose-finding study  [41] and no safety or toxicology study of any kind  [1].

## Frequently asked questions
The questions below are the ones this compound actually generates, answered at the grade the evidence supports.

## References and citation manifest
Every source cited on this page is listed below with its type and year, and every URL was checked for an HTTP 200 response on 2026-08-14. The machine-readable citation manifest ships alongside the page.

## Study results
| Study | Species/model | n | Duration | Outcome | Effect size |
| --- | --- | --- | --- | --- | --- |
| S01 (https://europepmc.org/article/MED/12195242) [provenance: originating-group; substance: Epitalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | human (Study of epitalon in Campbell rats and in patients with degenerative retinal lesions, reported in one paper) | Not stated in the abstract | Not stated in the abstract | The authors report a positive clinical effect in 90 percent of cases. The abstract gives no patient count, no control group, no randomization, no blinding and no outcome measure, and it reports the rat experiment and the patient experience in the same four sentences. This is the only record in the archived epitalon corpus carrying a Clinical Trial publication tag. | A single percentage with no denominator |
| S02 (https://europepmc.org/article/MED/17969590) [provenance: originating-group; substance: Epithalamin (pineal extract) and epitalon; in Russian; Not randomized · Not blinded] | human (Comparison of pineal peptide preparations in aged Macaca mulatta and in elderly people) | Not stated in the abstract | Not stated in the abstract | Authors report that both preparations restore night release of endogenous melatonin in people whose pineal function is already reduced. The same abstract states the preparations have no side effects, a claim made by the group that developed them and unsupported by any dedicated safety study. | Direction only |
| S03 (https://europepmc.org/article/MED/14647006) [provenance: originating-group; substance: Epitalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | human cells (ex vivo) (Cultured lymphocytes taken from older donors, treated in the dish) | Donors aged 76 to 80; count not stated in the abstract | Not stated in the abstract | Reported activation of ribosomal genes and decondensation of heterochromatin. The cells came from people; the peptide never entered a person in this experiment. | Not quantified in the abstract |
| S04 (https://europepmc.org/article/MED/31761987) [provenance: originating-group; substance: AEDG peptide (epitalon); in English; Not randomized · Not blinded] | human cells (ex vivo) (Phytohaemagglutinin-stimulated blood lymphocytes, telomere length by fluorescence in situ hybridization) | 11 men (5 aged 18 to 22, 6 aged 49 to 54) | Single incubation | Telomere length changed significantly in 7 of 11 donors: it INCREASED in 5 (by 41, 55, 156, 18 and 76 percent) and DECREASED in 2 (by 37 and 15 percent). The authors describe a tendency toward normalization rather than lengthening. This is the study most often cited as proof that epitalon lengthens telomeres in humans; it is a dish experiment on donated cells with eleven donors and a result that moves in both directions. | Bidirectional; 5 increases, 2 decreases, 4 no significant change |
| S05 (https://europepmc.org/article/MED/24323970) [provenance: independent; substance: Epitalon (synthetic tetrapeptide); in Russian; Not randomized · Not blinded] | human cells (ex vivo) (Short-term mitogen-stimulated cell cultures from tuberculosis patients before and after treatment) | Not stated in the abstract | Short-term culture | A protective effect on chromosome aberrations after treatment, but high chromosome fragility persisted with the peptide in both conditions. An independent Georgian group, working in cell culture rather than in patients. | Partial; one endpoint improved, one did not |
| S06 (https://europepmc.org/article/MED/28252435) [provenance: independent; substance: Ala-Glu-Asp-Gly (epitalon); in Russian; Not randomized · Not blinded] | human cells (ex vivo) (Lymphocyte cultures from breast cancer patients, peptide alone and with nickel ions) | Not stated in the abstract | Cell culture | A protective effect on genome instability markers is reported; the authors frame it as grounds for further study, not as a therapy. | Not quantified in the abstract |
| S07 (https://europepmc.org/article/MED/16705247) [provenance: independent; substance: Epitalon, Livagen and Vilon; in English; Not randomized · Not blinded] | human cells (ex vivo) (Cultured lymphocytes from old donors; heterochromatin decondensation measured) | Donors aged 75 to 88; count not stated in the abstract | Cell culture | An independent Tbilisi group reports the same class of chromatin effect the originating group reports. It is the clearest independent corroboration in the human-cell literature, and it is still a dish experiment. | Not quantified in the abstract |
| S08 (https://europepmc.org/article/MED/14523363) [provenance: originating-group; substance: Epithalamin (pineal peptide EXTRACT) with Thymalin, not epitalon; in English; Randomization not described · Not blinded] | human (Clinical assessment of 266 elderly and older people over 6 to 8 years, bioregulators given in the first 2 to 3 years) | 266 | 6 to 8 years of observation | Reported mortality reductions of 1.6 to 1.8 fold in the Epithalamin group, 2.0 to 2.1 fold with Thymalin, 2.5 fold with both, and 4.1 fold in a subgroup given both annually for 6 years. This is the study behind almost every longevity claim made for epitalon. It did not test epitalon. It tested Epithalamin, the pineal peptide extract from which the tetrapeptide was later derived, and it was reported by the people who developed both. | Fold reductions in mortality; no confidence intervals in the abstract |
| S09 (https://europepmc.org/article/MED/22451889) [provenance: originating-group; substance: Epithalamin (pineal peptide EXTRACT), not epitalon; in English; Randomized · Blinding not described] | human (Randomized comparative study; 39 patients received epithalamin courses plus basic therapy, 40 received basic therapy alone) | 79 (39 treated, 40 control) | 15 years of follow-up | Reported slower cardiovascular aging, preserved physical endurance, normalized melatonin rhythm and significantly lower mortality. It is described as randomized and it is the strongest human study anywhere near this compound. Three things bound it: it is 79 people, it studied the extract rather than the tetrapeptide, and the paper's own title says pituitary gland while its abstract says pineal gland. | Direction reported; magnitudes not given in the abstract |
| S10 (https://europepmc.org/article/MED/15452611) [provenance: originating-group; substance: Epithalamin (pineal peptide EXTRACT), not epitalon; in English; Randomized · Blinding not described] | human (Before-and-after course treatment, tagged as a randomized controlled trial in the literature index) | Not stated in the abstract | One course | Melatonin rose during darkness in subjects whose pineal activity was already low and TENDED TO FALL in subjects with normal pineal function. The effect is a normalization, not an increase, which is not how the compound is sold. | Bidirectional by baseline |
| S11 (https://europepmc.org/article/MED/18214303) [provenance: originating-group; substance: Epithalamin (pineal peptide EXTRACT), not epitalon; in English; Not randomized · Not blinded] | human (Observation of seasonal rhythm parameters over 30 months after 6 courses) | Not stated in the abstract | 30 months | Retained seasonal rhythms of thymic serum factor and hydrocortisone and higher autumn T cell counts, described as associated with a benign clinical course. | Not quantified in the abstract |
| S12 (https://europepmc.org/article/MED/12937682) [provenance: originating-group; substance: Epithalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | in vitro (Telomerase-negative human fetal fibroblast culture) | Cell culture | Not stated in the abstract | Induced expression of the telomerase catalytic subunit, telomerase enzyme activity and telomere elongation. This is the origin of every telomerase claim made for epitalon, and it is a dish of fetal lung fibroblasts. | Not quantified in the abstract |
| S13 (https://europepmc.org/article/MED/15455129) [provenance: originating-group; substance: Epithalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | in vitro (Primary pulmonary fibroblasts from a 24-week fetus, aged in culture to passage 34) | Cell culture | Followed to passage 44 | Telomeres in senescent cells lengthened back toward early-passage size and treated cells made 10 extra divisions past the control's limit. This is the single result behind the phrase overcoming the Hayflick limit. It is one cell line in one laboratory, and it has not been repeated in a whole animal by anyone. | 10 additional passages versus control |
| S14 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/) [provenance: independent; substance: Epitalon (synthetic tetrapeptide), purchased from a research-chemical vendor; in English; Not randomized · Not blinded] | in vitro (21NT and BT474 breast cancer lines, IBR.3 fibroblasts and HMEC epithelial cells; qPCR telomere length, hTERT expression, telomerase and ALT assays) | 4 cell lines | 4 days to 3 weeks | Dose-dependent telomere lengthening in normal cells through hTERT and telomerase, and lengthening in cancer cells through alternative lengthening of telomeres. Twenty-two years after the original claim, an independent laboratory reproduced it, quantitatively, in a dish. The same paper reports telomere SHORTENING at the lowest concentration in one cancer line, names its own main limitation as being a two-dimensional in vitro study, calls for in vivo work, and carries a published correction replacing three figures. | Telomere length 2.4 kb to 4 kb in 21NT at 0.5 and 1 micrograms per mL; maximum 8 kb in BT474 at 0.2 micrograms per mL |
| S15 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356729/) [provenance: collaboration; substance: AEDG (epitalon); in English; Not randomized · Not blinded] | in vitro (High-glucose-injured human retinal pigment epithelial line ARPE-19) | Cell line | Not stated in the abstract | Restored impaired wound healing and suppressed high-glucose-induced epithelial-mesenchymal transition. Led from an Italian university, with Khavinson and Trofimova among the authors. Its own conclusion asks for more work to confirm benefit AND safety. | Not quantified in the abstract |
| S16 (https://europepmc.org/article/MED/35413689) [provenance: independent; substance: Epitalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | in vitro (mouse oocytes) (Mouse oocytes aged in vitro for 6, 12 and 24 hours) | Oocyte cultures | Up to 24 hours | Reduced reactive oxygen species, fewer spindle defects and better mitochondrial membrane potential. An independent Chinese group. | Not quantified in the abstract |
| S17 (https://europepmc.org/article/MED/39788414) [provenance: independent; substance: Epitalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | in vitro (bovine oocytes) (Bovine cumulus-oocyte complexes and post-thawed embryos, in vitro embryo production) | Oocyte and embryo cultures | In vitro production cycle | Improved maturation rate and blastocyst hatching through telomerase activation. An independent Korean group, and the most recent independent replication of the telomerase mechanism outside human cells. | Significant at p less than 0.05; magnitudes not in the abstract |
| S18 (https://europepmc.org/article/MED/14501183) [provenance: originating-group; substance: Epitalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | mouse (Female outbred Swiss-derived SHR mice, treated from 3 months of age until natural death) | 54 per group | Life-long | The primary lifespan result was NULL: no effect on mean lifespan, food intake or body weight. What did change was narrower: the lifespan of the last 10 percent of survivors rose 13.3 percent, maximum lifespan rose 12.3 percent, chromosome aberrations fell 17.1 percent, and leukemia incidence fell 6-fold with no change in total tumor incidence. | Mean lifespan unchanged; maximum lifespan plus 12.3 percent |
| S19 (https://europepmc.org/article/MED/18856211) [provenance: originating-group; substance: Epithalon (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | rat (Female rats under standard, natural northern and constant illumination) | Not stated in the abstract | Life-long | Under a standard day and night cycle the peptide did NOT change lifespan at all. Effects appeared only in rats whose light exposure had already shortened their lives. Read plainly, the geroprotector rescued a stressor rather than extending a normal life. | No lifespan change under standard light; maximum lifespan plus 95 and 24 days under disrupted light |
| S20 (https://europepmc.org/article/MED/19110597) [provenance: originating-group; substance: Epithalone (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | rat (Male rats under permanent, natural northern or standard illumination) | Not stated in the abstract | Life-long | Again virtually no change in mean lifespan. The reported wins are a slower population aging rate and fewer spontaneous tumors, primarily testicular leydigomas and leukemias. | Mean lifespan virtually unchanged |
| S21 (https://europepmc.org/article/MED/12459848) [provenance: originating-group; substance: Epithalon (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | mouse (Female FVB/N HER-2/neu transgenic mice treated from month 2 to death) | Not stated in the abstract | Life-long | Mean and maximum lifetime longer by 13.5 and 13.9 percent, tumor-free lifetime longer by 34.2 percent, fewer breast adenocarcinomas and metastases. This is the strongest positive lifespan result in the file and it sits on the dose that does not match the rest of the literature. | Mean lifetime plus 13.5 percent (p less than 0.05) |
| S22 (https://europepmc.org/article/MED/12209581) [provenance: collaboration; substance: Epitalon (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | mouse (Female FVB/N HER-2/neu transgenic mice, epitalon versus Vilon versus saline) | Not stated in the abstract | From 2 months of age | Fewer and smaller mammary tumors and a 3.7-fold fall in HER-2/neu mRNA. The comparison peptide Vilon made things significantly WORSE, which is a useful reminder that short peptides are not interchangeably benign. Published in a mainstream oncology journal with Italian co-authors. | Cumulative tumor number and maximum size reduced, p less than 0.05 |
| S23 (https://europepmc.org/article/MED/12049808) [provenance: originating-group; substance: Epitalon (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | rat (80 male LIO rats given 1,2-dimethylhydrazine 21 mg per kg weekly, in four treatment schedules) | 80 | Whole experiment | Colon tumors per rat fell from 4.1 in controls to 2.7 with continuous treatment. Carcinomas still developed in 90 to 100 percent of animals in every group. | 4.1 versus 2.7 tumors per rat |
| S24 (https://europepmc.org/article/MED/16634527) [provenance: collaboration; substance: Epitalon (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | mouse (One-year-old female C3H/He mice kept 6.5 months) | Not stated in the abstract | 6.5 months | Fewer malignant tumors and no metastases in treated mice versus 3 of 9 tumor-bearing controls. The authors also state that long-term exposure at these small doses showed no toxic effect, which is the closest thing to a safety observation in the animal file and is not a toxicology study. | 0 of treated mice with metastases versus 3 of 9 controls |
| S25 (https://europepmc.org/article/MED/12360351) [provenance: originating-group; substance: Epithalon (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | mouse (SAMP-1, SAMR-1 and SHR mice treated from 2 months of age) | Not stated in the abstract | From 2 months of age | Chromosome aberrations fell 20, 30.1 and 17.9 percent in the three strains. Melatonin in drinking water had no such effect in the same experiment. | 17.9 to 30.1 percent fewer aberrant cells |
| S26 (https://europepmc.org/article/MED/11524632) [provenance: originating-group; substance: Epitalon (synthetic tetrapeptide); in English; Not randomized · Not blinded] | monkey (Female Macaca mulatta of different ages, melatonin and cortisol by immunoassay) | Not stated in the abstract | Not stated in the abstract | Reported stimulation of evening melatonin synthesis and normalization of the cortisol rhythm in senescent monkeys. The nearest thing to a human-relevant in vivo result, in six monkeys' worth of primate physiology at most. | Not quantified in the abstract |
| S27 (https://europepmc.org/article/MED/11087911) [provenance: originating-group; substance: Epitalon (Ala-Glu-Asp-Gly); in English; Not randomized · Not blinded] | fruit fly (Drosophila melanogaster, wild strain Canton-S) | Not stated in the abstract | Developmental exposure, lifespan followed | Adult lifespan 11 to 16 percent longer, with no dose-response: the effect did not depend on dose across five orders of magnitude, which is unusual enough that the authors remark on it. | Lifespan plus 11 to 16 percent, dose-independent |
| S28 (https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22) [substance: Epitalon (synthetic tetrapeptide); in n/a; Randomization not described · Blinding not described] | n/a (Publication-type search of the indexed literature) | 0 records | n/a | Europe PMC returns ZERO records for epitalon carrying a Randomized Controlled Trial tag, zero meta-analyses and zero systematic reviews. The same query over the epithalamin corpus returns 5 records tagged as randomized controlled trials. The randomized evidence in this family belongs to the extract, not to the peptide sold as epitalon. | n/a |
| S29 (https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22) [substance: Epitalon (synthetic tetrapeptide); in n/a; Randomization not described · Blinding not described] | n/a (Search of the archived corpus for any human PK measurement) | 0 studies | n/a | No published human pharmacokinetic study of epitalon was found in 167 archived records. There is no measured half-life, no bioavailability figure for any route, no Cmax and no AUC. A 2026 review preprint independently states that no human pharmacokinetic studies have been reported. | n/a |
| S30 (https://clinicaltrials.gov/search?term=epitalon) [substance: Epitalon, epithalon and epithalamin; in n/a; Randomization not described · Blinding not described] | n/a (ClinicalTrials.gov API v2 query) | 0 registered studies | n/a | A query for epitalon OR epithalon OR epithalamin returned totalCount 0 on 2026-08-14. Nobody is currently registered to run a trial of this compound in the United States or anywhere else that registry covers. | n/a |
| S31 (https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22) [substance: Epitalon (synthetic tetrapeptide); in n/a; Randomization not described · Blinding not described] | n/a (Provenance census of every human record in the archived corpus) | 0 studies | n/a | Every record in which epitalon or epithalamin was administered to a living person carries an author from the network that created the compound. The independent work that exists (Tbilisi, Brunel, Shanxi, Gyeongsang) is entirely in cell culture or in animals. No laboratory outside that network has published a study in which epitalon was given to a human being. | n/a |
| S32 (https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) [substance: Epitalon (synthetic tetrapeptide); in n/a; Randomization not described · Blinding not described] | n/a (Search of the archived corpus for toxicology or adverse-event studies) | 0 studies | n/a | No dedicated safety study, no toxicology study, no adverse-event surveillance and no long-term human safety data exist. The reassuring statements in the literature (no side effects, no toxic effect) appear inside efficacy papers written by the originating group. FDA states separately that it lacks sufficient information to know whether epitalon would cause harm if administered to humans. | n/a |

## What we do not know yet
What is unresolved about epitalon is structural rather than incidental, and it comes down to who has looked.

Of the 167 records a reproducible Europe PMC query returns for this peptide, 111 carry Khavinson or Anisimov as an author or name the St. Petersburg Institute of Bioregulation and Gerontology in the affiliation. That is 66.5 percent, and Khavinson alone is a named author on 100 of them. Almost everything known about this compound comes from the laboratory that invented it. That is a description of a research program, not an accusation, and the program is a real one that has run for four decades. But it means the central test that medicine applies to a claim, someone with no stake in the answer trying to get the same result and reporting it either way, has been applied to this compound only recently and only in cells.

The independent work that exists is genuine and it is worth naming precisely. Tbilisi State University reproduced chromatin decondensation in lymphocyte cultures in 2006. Shanxi Medical University reported protection of aging mouse oocytes in 2022. Gyeongsang National University reported telomerase-mediated improvements in bovine oocytes in 2025. And in 2025 Brunel University London reproduced dose-dependent telomere lengthening in human cell lines, quantitatively, twenty-two years after the original claim. Every one of those is in cells or in animal gametes. No laboratory outside the originating network has published a study in which epitalon was given to a human being.

The second structural gap is a substitution. The mortality and longevity results that sell this compound belong to Epithalamin, a peptide complex extracted from the pineal gland, not to the synthetic tetrapeptide in the vial. Five records in the epithalamin literature carry a randomized-controlled-trial tag; zero records in the epitalon literature do. The conflation is not purely commercial: PubChem's own synonym list for the tetrapeptide includes Epithalamin and Epithalamine. But the effect of it is that a buyer reads a 4.1-fold mortality reduction and orders something that was not in that study.

Then there are the ordinary absences, which are total. No human pharmacokinetic study, so no half-life, no bioavailability, no exposure figure for any route. No registered trial anywhere. No dose-finding study, and published regimens that disagree by up to four orders of magnitude, including one rodent dose a thousand times its neighbours that is most likely a units error in its source. No dedicated safety or toxicology study, no adverse-event surveillance, and no long-term human data. FDA's own position is that it lacks sufficient information to know whether epitalon would cause harm if administered to humans.

Two specific open questions deserve naming rather than burying. The independent 2025 study found telomere lengthening in breast cancer cell lines through alternative lengthening of telomeres, a mechanism cancer cells use to keep dividing; nobody knows what that means for a person, in either direction. And in the originating group's own mouse experiments, the sibling peptide Vilon significantly increased cancer incidence, which is direct evidence that short peptides cannot be assumed benign as a class.

What would change this page: an in vivo animal replication from an independent laboratory, which the Brunel authors themselves call for; any human study of epitalon rather than the extract; a pharmacokinetic measurement; and the final FDA determination, which is pending. We will date each change when it happens.

## Questions and answers
### Is epitalon FDA approved?
No. Epitalon is not FDA approved. It is sold for research use; no human efficacy has been established, and FDA has proposed not to permit it in compounded drugs. A Drugs@FDA search for epitalon as an active ingredient returns no matches.

No. Epitalon is not FDA approved. It is sold for research use; no human efficacy has been established, and FDA has proposed not to permit it in compounded drugs.Both halves are separately checkable. A Drugs@FDA query for epitalon as an active ingredient returns no matches, and so does the spelling epithalon. And FDA lists Epitalon on its page of bulk drug substances that may present significant safety risks in compounding, in the table of substances nominated but withdrawn.

### Does epitalon actually lengthen telomeres?
In cells, yes, and it has now been independently replicated: a 2025 Brunel University London study found dose-dependent telomere lengthening in human cell lines. In people, nobody has measured it. No study has given epitalon to a person and measured their telomeres.

This question splits cleanly by grade, and the split is the honest answer.In vitro: yes. The original 2003 experiment added the peptide to telomerase-negative human fetal fibroblast culture and reported telomerase induction and telomere elongation. A 2004 follow-up reported treated fibroblasts making 10 extra divisions past the control's limit, which is where the phrase overcoming the Hayflick limit comes from. In 2025, twenty-two years later, an independent laboratory at Brunel University London reproduced dose-dependent telomere lengthening in human cell lines, through hTERT and telomerase in normal cells and through alternative lengthening of telomeres in cancer cells. That same paper reports telomere shortening at its lowest concentration in one cancer line, names its main limitation as being a two-dimensional in vitro study, and carries a published correction replacing three figures.In people: unmeasured. There is no study in which epitalon was given to a person and their telomeres were then measured. The study usually cited for the human claim treated blood lymphocytes from 11 men in a dish: telomere length rose in 5 donors, by 41, 55, 156, 18 and 76 percent, and fell in 2, by 37 and 15 percent. The authors describe it as a tendency toward normalization, not as lengthening.

### What about the studies showing epitalon reduced mortality in elderly people?
Those studies tested Epithalamin, the pineal peptide extract, not epitalon the tetrapeptide. They are real publications, they are uncontrolled or small, and they were run by the developers of both preparations.

The mortality numbers are real, and they are about a different substance.The largest study assessed 266 elderly people over 6 to 8 years and reported mortality reductions of 1.6 to 1.8 fold for Epithalamin, 2.5 fold for Epithalamin plus Thymalin, and 4.1 fold in a subgroup given both annually for six years. Its abstract states no allocation method, no confidence intervals and no p values, and epitalon is not mentioned in it.The strongest single result is a 15-year follow-up of 39 elderly coronary patients given six epithalamin courses against 40 controls, which describes itself as randomized and reports significantly lower mortality. That is a genuine randomized signal in 79 people, from the same research network, about the extract.What these can show is that a group treating elderly patients with pineal peptide preparations over years reported better survival than their comparison groups. What they cannot show is that epitalon does this, at what dose, or that anyone outside that network can reproduce it.

### Who has actually studied epitalon?
Overwhelmingly one research network. Of 167 indexed records, 111 (66.5 percent) carry Khavinson or Anisimov as an author or name the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson alone is on 100 of them.

Almost everything known about epitalon comes from the laboratory that invented it.A four-term Europe PMC query returns 167 records. 111 of them, 66.5 percent, carry Vladimir Khavinson or Vladimir Anisimov as an author or name the St. Petersburg Institute of Bioregulation and Gerontology in the affiliation. Khavinson personally is a named author on 100, which is 59.9 percent of the entire literature. The census is recomputable from the archived records.This is stated as provenance, not as an accusation. That institute did the original work and has published on it for four decades. But the independent literature that exists is small and is entirely in cells and animals: Tbilisi State University on chromatin in lymphocyte cultures, Shanxi Medical University on mouse oocytes, Gyeongsang National University on bovine oocytes, and Brunel University London on telomere length in human cell lines. No laboratory outside that network has published a study in which epitalon was given to a human being.

### Is epitalon the same thing as epithalamin?
No. Epithalamin is a peptide complex extracted from the pineal gland; epitalon is a synthetic four-amino-acid sequence derived from that work. The human evidence divides along exactly that line, and the randomized studies are on the extract.

No, and the difference decides most arguments about this compound.The literature states it plainly: one 2007 abstract distinguishes Epithalamin, a complex of peptides isolated from the pineal gland, from Epitalon, a synthetic tetrapeptide, in a single sentence.Run one publication-type query over each literature and the split becomes a number: five records in the epithalamin corpus carry a Randomized Controlled Trial tag, and zero records in the epitalon corpus do.The conflation is not only a marketing habit. PubChem's synonym list for the tetrapeptide, CID 219042, includes both Epithalamin and Epithalamine. If the chemical databases blur it, a product page will blur it too, usually by borrowing the extract's mortality figures for the peptide in the vial.

### How does epitalon compare to selank and semax?
Only by nationality. Selank and semax are neuroactive peptides studied for anxiety and stroke; epitalon is a geroprotector candidate with a telomere mechanism. All three are unapproved in the US and were on the same July 2026 FDA agenda.

They get grouped together because they are all Russian-developed research peptides that FDA brought to the same advisory committee. The science has almost nothing in common.Selank is a tuftsin derivative studied as an anxiolytic, and semax is an ACTH fragment studied in stroke and cognition; both are given intranasally and both have human clinical literatures, mostly Russian-language and mostly uncontrolled. Epitalon is a pineal tetrapeptide studied as a geroprotector, given by injection, with a mechanism story about telomerase and a human literature that is one uncontrolled report plus a set of studies about a different substance.The regulatory position is the one thing they share. At the July 23 to 24, 2026 meeting FDA proposed that epitalon and semax both not be added to the 503A Bulks List, and neither is approved for any use. We cover selank at selankco.com and semax at semaxlabs.com, and every cross-compound figure on this page was verified against the primary source rather than copied between sites.

### What happened at the FDA advisory committee meeting in July 2026?
FDA proposed that Epitalon (free base) and Epitalon acetate NOT be included on the 503A Bulks List. Inclusion would not have meant approval; it governs what pharmacists may compound with. The rulemaking is still pending.

Epitalon was on the July 24, 2026 morning agenda. FDA's Points to Consider, items 11 and 12, read: FDA is proposing that Epitalon (free base) NOT be included on the 503A Bulks List, and FDA is proposing that Epitalon acetate NOT be included on the 503A Bulks List.Two clarifications matter. Inclusion on that list is not approval: it governs what a licensed pharmacist may compound with, inside the statutory exemptions from new drug approval, from labeling with adequate directions for use, and from current good manufacturing practice.And both nominations to add epitalon had already been withdrawn by the nominators. FDA elected to present the substance anyway. The agency states it will not issue a final determination until advisory input has been considered and all reviews finalized, so the rulemaking is pending. We state FDA's proposal, which is written down, and make no claim about how the committee voted, because no tally was posted on FDA's meeting page when this page was built.

### What dose of epitalon do the studies use?
There is no established human dose. Rodent studies cluster at 0.1 to 1.0 micrograms per animal, cell work at 0.1 to 1.0 micrograms per mL, and the human reports state no dose at all. No dose-finding study has ever been published.

There is no established human dose of epitalon, and the published numbers disagree by up to four orders of magnitude.Most rodent studies use 0.1 to 1.0 micrograms per animal, given five consecutive days each month or five days a week. One outlier states 1 mg per mouse, roughly a thousand times higher than its neighbours; we reproduce it as published and flag it as a probable units error in the source. Cell work runs 0.1 to 1.0 micrograms per mL or 0.1 mM.The human reports state no dose at all. The retinitis pigmentosa paper gives none, and the epithalamin cohort studies describe courses without stating milligrams. Our study-dose explorer shows every regimen with the study that used it, its species, its design and its provenance, and computes nothing that resembles a recommendation.

### Is epitalon safe?
Nobody knows. No dedicated human safety study, no toxicology study and no long-term data exist. FDA states it lacks sufficient information to know whether epitalon would cause harm if administered to humans.

Nobody knows, and that is the accurate answer rather than a cautious one.No dedicated human safety study of epitalon exists, no toxicology study exists, and there is no long-term data at any dose. The reassuring statements that circulate are real sentences from real papers and they are not safety findings: having no side effects appears inside a 2007 efficacy abstract from the originating group, and long-term exposure did not show any toxic effect appears inside a 6.5-month mouse tumor study.Against them: FDA states it lacks sufficient information to know whether epitalon would cause harm if administered to humans, and flags immunogenicity risk from aggregation and peptide-related impurities. In the same laboratory's mouse experiments the comparison peptide Vilon significantly increased cancer incidence, which shows short peptides are not benign as a class. And with no pharmacokinetic study, the exposure a given dose produces is unmeasured.

### Is there any reason for concern if you have or have had cancer?
The independent 2025 study found epitalon lengthening telomeres in breast cancer cell lines through alternative lengthening of telomeres, a mechanism cancer cells use to keep dividing. No human data exists either way.

This is a real open question rather than a formality, and it comes from the most independent paper in the file.The 2025 Brunel study reports that in the breast cancer lines 21NT and BT474, epitalon extended telomeres through alternative lengthening of telomeres, one of the two mechanisms cancer cells use to avoid the division limit. The authors observed only a minor increase in that activity in normal cells and read the overall result as reassuring for healthy tissue.We report the cancer-cell finding neutrally because a reader deciding whether to inject a telomerase activator should see it. The animal tumor literature points the other way, with fewer and smaller tumors in several rodent models. Neither answers the human question, because no human study of any kind exists in people with cancer.

### Does epitalon extend lifespan in animals?
Inconsistently. The best-designed mouse study found no change in mean lifespan, only in maximum lifespan. Two rat studies found no lifespan change under a normal light cycle. Fruit fly lifespan rose 11 to 16 percent with no dose-response.

The animal record is the largest positive body of evidence for this compound, and it is more interesting with the nulls left in.In 54 female SHR mice per group treated monthly for life, epitalon did not change mean lifespan at all. Maximum lifespan rose 12.3 percent, the last 10 percent of survivors lived 13.3 percent longer, chromosome aberrations fell 17.1 percent, and leukemia fell 6-fold with no change in total tumor incidence.Two rat studies found no change in mean lifespan under a standard day and night cycle; effects appeared only in animals whose lives had already been shortened by disrupted illumination. The strongest positive result, 13.5 percent longer mean lifetime in transgenic mice, sits on the dose that does not match the rest of the literature.

### Are there any registered clinical trials of epitalon?
None. A ClinicalTrials.gov query for epitalon, epithalon or epithalamin returns zero registered studies. The indexed literature also contains zero randomized trials, zero meta-analyses and zero systematic reviews of epitalon.

None, and the surrounding absences are just as informative.A ClinicalTrials.gov query for epitalon OR epithalon OR epithalamin returns zero registered studies. Nobody is currently registered to run a trial of this compound anywhere that registry covers.In the published literature, zero epitalon records carry a Randomized Controlled Trial publication tag, and there are zero meta-analyses and zero systematic reviews. The same query over the epithalamin literature returns five randomized-tagged records, which is another way of seeing that the trial evidence in this family belongs to the extract and not to the peptide sold as epitalon.

### What is actually in a vial of epitalon?
Nobody independent has checked. There is no approved product, no assigned strength, no expiry set by any authority and no quality standard. The mass on the label is the seller's claim.

A sealed vial of lyophilized powder whose mass, purity and identity rest entirely on the seller's word.There is no approved product, so there is no labeled strength, no expiry set by any authority and no manufacturing standard behind the number printed on the vial. FDA's specific technical concern for this class of preparation is aggregation and peptide-related impurities, which are exactly the failure modes a seller-supplied certificate of analysis is least able to rule out.For calibration, consider what a university laboratory does. The independent 2025 replication also bought its epitalon from a research-chemical vendor and recorded dissolving 10 mg in 4 mL of bacteriostatic water to reach 2.5 mg per mL, reporting no certificate of analysis, purity figure or independent identity confirmation. Our reconstitution calculator does the same arithmetic and says plainly that its starting number is unverified.

## References
1. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
2. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 https://www.fda.gov/media/193342/download
3. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee Meeting Announcement https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
4. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act https://www.fda.gov/media/94155/download
5. Drugs@FDA query for epitalon as an active ingredient https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
6. ClinicalTrials.gov search for epitalon OR epithalon OR epithalamin https://clinicaltrials.gov/search?term=epitalon
7. PubChem Compound Summary for CID 219042, Epitalon https://pubchem.ncbi.nlm.nih.gov/compound/219042
8. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. https://europepmc.org/article/MED/12937682
9. Peptide promotes overcoming of the division limit in human somatic cell. https://europepmc.org/article/MED/15455129
10. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/
11. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12619744/
12. Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes. https://europepmc.org/article/MED/31761987
13. Peptides of pineal gland and thymus prolong human life. https://europepmc.org/article/MED/14523363
14. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. https://europepmc.org/article/MED/22451889
15. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. https://europepmc.org/article/MED/15452611
16. Effect of epithalamin on the rhythm of immune and endocrine systems functioning in patients with chronic coronary disease. https://europepmc.org/article/MED/18214303
17. [Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people]. https://europepmc.org/article/MED/17969590
18. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. https://europepmc.org/article/MED/12195242
19. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. https://europepmc.org/article/MED/24003726
20. [Peptidergic regulation of expression of cellular aging marker proteins in buccal epithelium.] https://europepmc.org/article/MED/39742404
21. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. https://europepmc.org/article/MED/14501183
22. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice. https://europepmc.org/article/MED/12459848
23. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. https://europepmc.org/article/MED/12209581
24. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. https://europepmc.org/article/MED/12049808
25. Effect of Ala-Glu-Asp-Gly peptide on life span and development of spontaneous tumors in female rats exposed to different illumination regimes. https://europepmc.org/article/MED/18856211
26. Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. https://europepmc.org/article/MED/19110597
27. Effect of epitalon on the lifespan increase in Drosophila melanogaster. https://europepmc.org/article/MED/11087911
28. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. https://europepmc.org/article/MED/11524632
29. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. https://europepmc.org/article/MED/16634527
30. Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice. https://europepmc.org/article/MED/12360351
31. Peptide Epitalon activates chromatin at the old age. https://europepmc.org/article/MED/14647006
32. Anti-aging peptide bioregulators induce reactivation of chromatin. https://europepmc.org/article/MED/16705247
33. [GENOMIC VARIABILITY IN PATIENTS WITH DUCTAL FORM OF BREAST CANCER AND THE POSSIBILITY OF CORRECTION THE PEPTIDE BIOREGULATOR AND METAL IONS]. https://europepmc.org/article/MED/28252435
34. [Genome instability in pulmonary tuberculosis before and after treatment]. https://europepmc.org/article/MED/24323970
35. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. https://europepmc.org/article/MED/35413689
36. Epitalon-activated telomerase enhance bovine oocyte maturation rate and post-thawed embryo development. https://europepmc.org/article/MED/39788414
37. The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356729/
38. Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology. https://europepmc.org/article/MED/8010617
39. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13095733/
40. From Cellular Aging to Tissue Protection: Epitalon in Regenerative and Longevity Medicine https://europepmc.org/article/PPR/PPR1291309
41. Europe PMC query TITLE_ABS:"epitalon" OR TITLE_ABS:"epithalon" OR TITLE_ABS:"AEDG" OR TITLE_ABS:"Ala-Glu-Asp-Gly" https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22
42. Europe PMC query TITLE_ABS:"epithalamin" https://europepmc.org/search?query=TITLE_ABS%3A%22epithalamin%22
43. Publication-type counts over the epitalon query (Randomized Controlled Trial, Meta-Analysis, Systematic Review) https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22
44. Provenance census of the 167 archived epitalon records https://europepmc.org/search?query=TITLE_ABS%3A%22epitalon%22
45. epithalonrx content/articles-index.json https://epithalonrx.com/